AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Aardvark Therapeutics (NASDAQ: AARD) and noted that a federal class action has been filed. Investors who bought shares in or traceable to Aardvark's February 13, 2025 IPO, or held securities between February 13, 2025 and May 14, 2026, have until October 13, 2026 to seek appointment as lead plaintiff.

Analysis

This is a plaintiff-law-firm solicitation, not a new operating disclosure or adjudicated liability finding; its standalone informational value is low. The near-term market effect is nonetheless asymmetric for AARD because a recently public, development-stage biotech typically has limited fundamental anchors and a concentrated retail holder base, making incremental legal headlines capable of widening liquidity discounts and raising financing-cost concerns.

The relevant transmission channel is not likely direct damages but capital access. If litigation prompts risk-factor expansion, auditor scrutiny, or management distraction, investors may assign a higher probability of a discounted equity raise; that can pressure the stock over the next 1-3 months even absent a material court development. AARD's downside should be evaluated against cash runway, quarterly operating burn, trial timelines, and any shelf-registration capacity rather than the existence of the complaint itself.

Contrarian view: these notices frequently produce little durable price impact unless followed by a motion surviving dismissal, an SEC inquiry, a restatement, or revised clinical/commercial disclosures. A sharp selloff on this item alone could be overdone, but there is insufficient information to underwrite a long until the alleged disclosure gap and balance-sheet runway are independently assessed. Over 6-18 months, clinical readouts and financing terms—not litigation headlines—should determine valuation.

Key Decisions for Investors

• Do not initiate a directional position solely on this notice; treat it as a monitoring event rather than a fundamental catalyst.
• For existing AARD longs, reduce gross exposure or hedge through the next earnings/corporate update if cash runway is below 12 months or management does not explicitly address financing plans; a discounted raise is the key downside catalyst.
• Consider a tactical short only after a litigation-driven bounce fails and AARD breaks its prior 20-day low on sustained volume; cover if the company reaffirms runway beyond 18 months or no new adverse disclosure emerges by the next results update.
• Set alerts for an SEC investigation, amended complaint, motion-to-dismiss ruling, restatement, clinical-data revision, or S-3/ATM filing. The latter two would be more actionable negative signals than the current solicitation.